News

Publications

Oncology Tube

Interview with Ahmet Hoke, MD, PhD

 

CISION PR Newswire

AxoProtego Therapeutics Announces New CEO

View publication »

Ethoxyquin Prevents Chemotherapy-Induced Neurotoxicity via Hsp90 Modulation

Objective: Peripheral neurotoxicity is a major dose-limiting side effect of many chemotherapeutic drugs. Currently there are no effective disease-modifying therapies for chemotherapy-induced peripheral neuropathies, but these side effects of chemotherapy are potentially ideal targets for development of neuroprotective therapies, because candidate drugs can be co- or preadministered before the injury to peripheral axons takes place.    (To read more click view publication)

View publication »

CISION PR Newswire

AxoProtego Therapeutics Announces Novel Investigational Agent for Chemotherapy-Induced Peripheral Neuropathy

View publication »

Neurology

Trial designs for chemotherapy-induced peripheral neuropathy prevention3

View publication »

Wiley / PubMed

Multi‐center assessment of the Total Neuropathy Score for chemotherapy‐induced peripheral neurotoxicity2

View publication »
View publication »

NCIB logo

NCBI

Development of a High-Throughput Screening Cancer Cell-Based Luciferase Refolding Assay for Identifying Hsp90 Inhibitors4

View publication »

Asociación Española de Ciencia Avícola - AECA - WPSA

Safety and efficacy of ethoxyquin (6-ethoxy-1,2-dihydro-2,2,4-trimethylquinoline) for all animal species5

EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2015. Safety and efficacy of ethoxyquin (6‐ethoxy‐1,2‐dihydro‐2,2,4‐trimethylquinoline) for all animal species. EFSA Journal. 2015;13(11). doi:10.2903/j.efsa.2015.4272.

View publication »

PubMed

Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicity7

View publication »

PubMed

Ethoxyquin: An Antioxidant Used in Animal Feed1

View publication »

Bibliography

1 Błaszczyk A, Augustyniak A, Skolimowski J. Ethoxyquin: An Antioxidant Used in Animal Feed. International Journal of Food Science. 2013;2013:1-12. doi:10.1155/2013/585931.

2 Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System. 2006;11(2):135-141. doi:10.1111/j.1085-9489.2006.00078.x.

3 Gewandter JS, Brell J, Cavaletti G, et al. Trial designs for chemotherapy-induced peripheral neuropathy prevention. Neurology. 2018;91(9):403-413. doi:10.1212/wnl.0000000000006083.

4 Sadikot T, Swink M, Eskew JD, et al. Development of a High-Throughput Screening Cancer Cell-Based Luciferase Refolding Assay for Identifying Hsp90 Inhibitors. ASSAY and Drug Development Technologies. 2013;11(8):478-488. doi:10.1089/adt.2012.498.

5 Safety and efficacy of ethoxyquin (6‐ethoxy‐1,2‐dihydro‐2,2,4‐trimethylquinoline) for all animal species. EFSA Journal. 2015;13(11). doi:10.2903/j.efsa.2015.4272.

6 Zhu J, Chen W, Mi R, Zhou C, Reed N, Höke A. Ethoxyquin prevents chemotherapy-induced neurotoxicity via Hsp90 modulation. Annals of Neurology. 2013;74(6):893-904. doi:10.1002/ana.24004.

7 Zhu J, Carozzi VA, Reed N, et al. Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicity. Scientific Reports. 2016;6(1). doi:10.1038/srep28861.

Events